Throughout the year, there may be one or more clinical trials available worldwide for Acromegalics to participate in. By joining and participating in clinical trials, you are helping other patients not only with early diagnosis at times, awareness, and improving quality of life.
Bone MicroArchitecture Clinical Trial Seeking Volunteers
Are you doing your part to advance the understanding regarding acromegaly? There are several studies going on right now that are listed on www.clinicaltrials.gov
The following study, conducted by Dr. Pamela Freda of Columbia University, is now available for those located in the Northeastern USA and currently using Somavert. This would be a great way to get your foot into the door of working with a great doctor and to advance research.
Dr. Freda is conducting a study entitled Pilot Study of Bone Microarchitecture in Pegvisomant Treated Patients
. This study is open to patients treated with Pegvsiomant for at least 1 year with a normal IGF-1 level. It includes DXA, high resolution peripheral CT to examine bone micro architecture and measurement of bone markers and GH and IGF-1.
Requires a one-time 2-hour visit. The study is also registered on www.clinicaltrials.gov
. 13 spots available at time of posting.
Ongoing Crinetics Studies in Acromegaly
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CRN00808 IN PATIENTS WITH ACROMEGALY THAT ARE RESPONDERS TO OCTREOTIDE LAR OR LANREOTIDE DEPOT
This Phase 2 study is now recruiting adult patients with acromegaly at participating sites in the United States and Europe. Patients who are treated with Octreotide LAR or Lanreotide Depot as their sole acromegaly medication and have normal IGF-1 levels may be eligible to participate. This study is active and currently recruiting new patients. For more information on this study, please follow the ClinicalTrials.gov link: NCT03792555
AN OPEN LABEL EXPLORATORY STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CRN00808 IN PATIENTS WITH ACROMEGALY TREATED WITH SOMATOSTATIN ANALOGUE BASED TREATMENT REGIMENS
This phase 2 study is now recruiting adult patients at participating sites in the United States and Europe. Patients who are currently treated with somatostatin-based treatments (e.g. Octreotide, Lanreotide, Pasireotide) may be eligible to participate. This study is active and currently recruiting new patients. For more information on this study, please follow the ClinicalTrials.gov link: NCT03789656